Hao Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hao Tang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Kun-Peng Qin
Department of Orthopedics, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
1 shared publication - Rui Zhu
Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, 218 Jixi Road, Hefei 230022, China; Department of Orthopedics, Hefei Orthopedics Hospital, 58 Chaohu Northern Road, Hefei 238001, China
1 shared publication - Shuang Li
Department of Orthopedics, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
1 shared publication - Wen-Shan Shan
Department of Orthopedics, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
1 shared publication - Yu Kang
Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, 218 Jixi Road, Hefei 230022, China
1 shared publication - Zongsheng Yin
Department of Orthopedics, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
1 shared publication
Latest Publications
- Open Access
- 16 September 2022
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (4) , 881-888
Erythropoietin inhibits ferroptosis and ameliorates neurological function after spinal cord injury
JOURNAL/nrgr/04.03/01300535-202304000-00034/figure1/v/2026-05-25T155121Z/r/image-tiff Ferroptosis is one of the critical pathological events in spinal cord injury. Erythropoietin has been reported to improve the recovery of spinal cord injury. However, whether ferroptosis is involved in the neuroprotective effects of erythropoietin on spinal cord injury has not been examined. In this study, we established rat models of spinal cord injury by modified Allen’s method and intraperitoneally administered 1000 and 5000 IU/kg erythropoietin once a week for 2 successive weeks. Both low and high doses of erythropoietin promoted recovery of hindlimb function, and the high dose of erythropoietin led to better outcome. High dose of erythropoietin exhibited a stronger suppressive effect on ferroptosis relative to the low dose of erythropoietin. The effects of erythropoietin on inhibiting ferroptosis-related protein expression and restoring mitochondrial morphology were similar to those of Fer-1 (a ferroptosis suppressor), and the effects of erythropoietin were largely diminished by RSL3 (ferroptosis activator). In vitro experiments showed that erythropoietin inhibited RSL3-induced ferroptosis in PC12 cells and increased the expression of xCT and Gpx4. This suggests that xCT and Gpx4 are involved in the neuroprotective effects of erythropoietin on spinal cord injury. Our findings reveal the underlying anti-ferroptosis role of erythropoietin and provide a potential therapeutic strategy for treating spinal cord injury.
- 16 September 2022
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (4) , 881-888
Open AccessErythropoietin inhibits ferroptosis and ameliorates neurological function after spinal cord injury
JOURNAL/nrgr/04.03/01300535-202304000-00034/figure1/v/2026-05-25T155121Z/r/image-tiff Ferroptosis is one of the critical pathological events in spinal cord injury. Erythropoietin has been reported to improve the recovery of spinal cord injury. However, whether ferroptosis is involved in the neuroprotective effects of erythropoietin on spinal cord injury has not been examined. In this study, we established rat models of spinal cord injury by modified Allen’s method and intraperitoneally administered 1000 and 5000 IU/kg erythropoietin once a week for 2 successive weeks. Both low and high doses of erythropoietin promoted recovery of hindlimb function, and the high dose of erythropoietin led to better outcome. High dose of erythropoietin exhibited a stronger suppressive effect on ferroptosis relative to the low dose of erythropoietin. The effects of erythropoietin on inhibiting ferroptosis-related protein expression and restoring mitochondrial morphology were similar to those of Fer-1 (a ferroptosis suppressor), and the effects of erythropoietin were largely diminished by RSL3 (ferroptosis activator). In vitro experiments showed that erythropoietin inhibited RSL3-induced ferroptosis in PC12 cells and increased the expression of xCT and Gpx4. This suggests that xCT and Gpx4 are involved in the neuroprotective effects of erythropoietin on spinal cord injury. Our findings reveal the underlying anti-ferroptosis role of erythropoietin and provide a potential therapeutic strategy for treating spinal cord injury.